Chaby, L.E.; Lasseter, H.C.; Contrepois, K.; Salek, R.M.; Turck, C.W.; Thompson, A.; Vaughan, T.; Haas, M.; Jeromin, A.
Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609. Metabolites 2023, 13, 933.
https://doi.org/10.3390/metabo13080933
AMA Style
Chaby LE, Lasseter HC, Contrepois K, Salek RM, Turck CW, Thompson A, Vaughan T, Haas M, Jeromin A.
Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609. Metabolites. 2023; 13(8):933.
https://doi.org/10.3390/metabo13080933
Chicago/Turabian Style
Chaby, Lauren E., Heather C. Lasseter, Kévin Contrepois, Reza M. Salek, Christoph W. Turck, Andrew Thompson, Timothy Vaughan, Magali Haas, and Andreas Jeromin.
2023. "Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609" Metabolites 13, no. 8: 933.
https://doi.org/10.3390/metabo13080933
APA Style
Chaby, L. E., Lasseter, H. C., Contrepois, K., Salek, R. M., Turck, C. W., Thompson, A., Vaughan, T., Haas, M., & Jeromin, A.
(2023). Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609. Metabolites, 13(8), 933.
https://doi.org/10.3390/metabo13080933
